Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06901245 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tirzepatide in PWS, HO and GNSO

StatusRecruiting
PhasePhase 4
SponsorGrace Kim
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 16, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Site details revised at 2 of 3 sitesv3
  2. Start date changed from estimate of Mar 2025 to May 1, 2025v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Grace Kim
1 trial monitored
See all monitored trials
Obesity
3,874 trials monitored
See 152 trials at risk
This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.
Trial Details
NCT Number NCT06901245
Lead Sponsor Grace Kim
Collaborators: Vanderbilt University Medical Center, Children's Hospitals and Clinics of Minnesota, Seattle Children's Hospital
Conditions
(from sponsor)		 Prader-Willi Syndrome, Hypothalamic Obesity, Obesity/Therapy
Related terms Obesity, Prader-Willi Syndrome, Sexual Infantilism
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov